Bridging Nordic ATMPs is the new series of ATMP webinars hosted by the Nordic EATRIS Nodes (Sweden, Norway and Finland). In this series scientists will share updates on hot research topics in the field of ATMPs. We will also highlight funding and Nordic collaboration opportunities, when applicable.
This series will take place online 12.00-13.00 CEST, once a month starting 3 September 2025 with a lecture by an expert in the Advanced Therapy Medicinal Products (ATMPs) field.
3 September 2025
Navigating the Translational Journey: Bridging Academia and Industry in ATMP Development, Janet Hoogstraate, PhD, Chief Executive Officer at NorthX Biologics
As CEO of NorthX Biologics, Janet brings a vast amount of experience to the table. Most recently coming from a position as the managing director at Valneva, Janet has also worked in preclinical R&D at Astra Pain Control, as well as in various leadership positions in drug discovery and development in neuroscience. She is also a trusted board member of Mireca Medicines GmbH, Alzecure Pharma AB and APL AB. Janet has a PhD in biopharmaceutical sciences from Leiden University in the Netherlands and an EMBA from Hult International School in London.
1 October 2025
Prof. Joel Clinton Glover, Director of Norwegian Core Facility for Human Pluripotent Stem Cells at the University of Oslo and Oslo University Hospital.
Talk title: ” Establishing NIBCA – the Norwegian iPSC Biobank for Clinical Applications – GMP and pre-GMP activities in Oslo”
Joel Clinton Glover is currently leading the establishment of NIBCA – the Norwegian iPSC Biobank for Clinical Applications at Oslo University Hospital. His work focuses on developing the infrastructure and standards for GMP and pre-GMP production of iPSCs, supporting advanced therapy development across Norway. With deep expertise in stem cell research, translational neuroscience, and cell-based models of neurological disease, Glover brings a unique perspective on how to enable the clinical-grade application of iPSC technologies.
5 November 2025
Özcan Met, PhD, Associate Professor and Head of Cell Therapy Unit, at CCIT-DK and DTU HealthTech will be speaking on Translating Science into Therapies Through ATMP Development at the National Centre for Cancer Immune Therapy
Özcan Met has headed the Cell Therapy Unit at the National Centre for Cancer Immune Therapy in Denmark since 2010, directing all operational activities required for the manufacturing of cellular products intended for use in clinical trials. As Head of Cell Therapy, he has been responsible for the release of over 200 cell therapy products in Phase I, II, and III immunotherapy clinical trials. Özcan has more than 20 years of research experience in tailoring the immune system to combat cancer and leads a team at the cutting edge in the development of novel cell-based technologies for patient treatment.
3 December 2025
Erja Kerkelä, Development Manager, Docent (Associate Professor) at the Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, will be speaking on Building ATMP capabilities in a non-profit setting: insights from the Finnish Red Cross Blood Service
Erja Kerkelä holds a PhD in medicine and the title of Docent in cell biology, with over 20 years of experience in research and development. Her expertise spans stem cell and immune cell biology, as well as various aspects of cell therapy. Since 2010, she has worked at the Finnish Red Cross Blood Service, and from 2019, as Development Manager and Quality Control responsible person at the Advanced Cell Therapy Centre, the GMP unit of the Blood Service.
In her current role, she leads development projects for novel cell therapies, focusing on clinical translation, GMP compliance, and collaboration with clinicians and other partners in Finland and internationally. The unit serves as a local manufacturer of ATMPs and tissue products, enabling the production of cell therapies for clinical trials and patient treatments in Finland.
Next webinar: 2026
How to attend
Follow the link below to register. You will be asked which webinars in the series you would like to attend. Once you have registered you will receive an email with joining details.
